Loading...

Glaukos

DB:6GJ
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6GJ
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
6GJ Share Price and Events
7 Day Returns
1.9%
DB:6GJ
2.6%
DE Medical Equipment
0.3%
DE Market
1 Year Returns
105.6%
DB:6GJ
13.4%
DE Medical Equipment
-11.6%
DE Market
6GJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Glaukos (6GJ) 1.9% -2.6% -1% 105.6% 185.3% -
DE Medical Equipment 2.6% 2.6% 5.6% 13.4% 109.3% 237.2%
DE Market 0.3% -3.8% 2.5% -11.6% 10.1% 7.9%
1 Year Return vs Industry and Market
  • 6GJ outperformed the Medical Equipment industry which returned 13.4% over the past year.
  • 6GJ outperformed the Market in Germany which returned -11.6% over the past year.
Price Volatility
6GJ
Industry
5yr Volatility vs Market
Related Companies

6GJ Value

 Is Glaukos undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Glaukos to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Glaukos.

DB:6GJ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:6GJ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.895 (1 + (1- 21%) (0.5%))
0.932
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.932 * 5.96%)
5.78%

Discounted Cash Flow Calculation for DB:6GJ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Glaukos is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:6GJ DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.78%)
2019 23.00 Analyst x1 21.74
2020 47.00 Analyst x2 42.00
2021 70.00 Analyst x2 59.13
2022 89.33 Est @ 27.61% 71.33
2023 106.65 Est @ 19.39% 80.51
2024 121.20 Est @ 13.64% 86.50
2025 132.86 Est @ 9.62% 89.63
2026 141.90 Est @ 6.8% 90.49
2027 148.75 Est @ 4.83% 89.68
2028 153.88 Est @ 3.45% 87.70
Present value of next 10 years cash flows $718.72
DB:6GJ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $153.88 × (1 + 0.23%) ÷ (5.78% – 0.23%)
$2,776.05
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,776.05 ÷ (1 + 5.78%)10
$1,582.11
DB:6GJ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $718.72 + $1,582.11
$2,300.83
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,300.83 / 36.40
$63.2
DB:6GJ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:6GJ represents 0.89767x of NYSE:GKOS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89767x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 63.20 x 0.89767
€56.74
Value per share (EUR) From above. €56.74
Current discount Discount to share price of €59.83
= -1 x (€59.83 - €56.74) / €56.74
-5.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Glaukos is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Glaukos's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Glaukos's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6GJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.32
NYSE:GKOS Share Price ** NYSE (2019-05-21) in USD $66.65
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 35.68x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 20.29x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Glaukos.

DB:6GJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:GKOS Share Price ÷ EPS (both in USD)

= 66.65 ÷ -0.32

-205.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Glaukos is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Glaukos is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Glaukos's expected growth come at a high price?
Raw Data
DB:6GJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -205.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
64.7%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.02x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Glaukos, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Glaukos's assets?
Raw Data
DB:6GJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $5.11
NYSE:GKOS Share Price * NYSE (2019-05-21) in USD $66.65
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.16x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.79x
DB:6GJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:GKOS Share Price ÷ Book Value per Share (both in USD)

= 66.65 ÷ 5.11

13.06x

* Primary Listing of Glaukos.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Glaukos is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Glaukos's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Glaukos has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6GJ Future Performance

 How is Glaukos expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
64.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Glaukos expected to grow at an attractive rate?
  • Glaukos's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Glaukos's earnings growth is expected to exceed the Germany market average.
  • Glaukos's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6GJ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6GJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 64.7%
DB:6GJ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 16.7%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.8%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6GJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6GJ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 432 55 1
2022-12-31 409 30 2
2021-12-31 323 58 18 7
2020-12-31 274 37 4 10
2019-12-31 231 22 -9 10
DB:6GJ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 195 26 -12
2018-12-31 181 19 -13
2018-09-30 169 14 -14
2018-06-30 165 17 -6
2018-03-31 163 17 -4
2017-12-31 159 26 0
2017-09-30 151 17 -1
2017-06-30 140 14 -1
2017-03-31 127 16 5
2016-12-31 114 12 5
2016-09-30 102 8 2
2016-06-30 91 4 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Glaukos's earnings are expected to grow significantly at over 20% yearly.
  • Glaukos's revenue is expected to grow by 16.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6GJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Glaukos Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6GJ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.34 1.34 1.34 1.00
2022-12-31 0.88 0.88 0.88 1.00
2021-12-31 0.45 0.76 0.31 7.00
2020-12-31 0.07 0.30 -0.02 10.00
2019-12-31 -0.26 -0.12 -0.40 10.00
DB:6GJ Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.32
2018-12-31 -0.37
2018-09-30 -0.39
2018-06-30 -0.17
2018-03-31 -0.11
2017-12-31 0.00
2017-09-30 -0.03
2017-06-30 -0.03
2017-03-31 0.13
2016-12-31 0.14
2016-09-30 0.06
2016-06-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Glaukos is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Glaukos's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Glaukos has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6GJ Past Performance

  How has Glaukos performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Glaukos's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Glaukos does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Glaukos's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Glaukos's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Glaukos's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Glaukos Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6GJ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 195.17 -11.58 127.30 52.70
2018-12-31 181.28 -12.95 119.53 49.68
2018-09-30 168.85 -13.72 113.39 47.24
2018-06-30 165.36 -5.78 105.90 43.85
2018-03-31 163.48 -3.68 101.93 40.87
2017-12-31 159.25 -0.09 96.26 38.91
2017-09-30 150.78 -0.96 90.79 35.78
2017-06-30 139.94 -1.13 83.50 33.78
2017-03-31 127.21 4.50 73.95 31.10
2016-12-31 114.40 4.52 64.76 29.22
2016-09-30 101.50 2.10 56.65 28.12
2016-06-30 90.93 -1.12 51.04 26.49
2016-03-31 80.13 -35.38 48.43 26.87
2015-12-31 71.70 -37.24 43.96 25.05
2015-09-30 65.54 -39.56 40.50 24.06
2015-06-30 58.66 -38.99 35.94 22.98
2015-03-31 52.00 -9.14 30.00 20.06
2014-12-31 45.59 -12.13 28.14 19.21
2014-09-30 38.06 -10.56 24.04 18.07
2014-06-30 32.52 -12.11 22.21 17.15
2014-03-31 26.28 -12.85 19.84 16.35
2013-12-31 20.95 -12.64 17.10 15.51
2012-12-31 2.43 -19.33 9.57 13.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Glaukos has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Glaukos has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Glaukos improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Glaukos's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Glaukos has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6GJ Health

 How is Glaukos's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Glaukos's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Glaukos is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Glaukos's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Glaukos's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 15.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Glaukos Company Filings, last reported 1 month ago.

DB:6GJ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 185.49 12.17 145.26
2018-12-31 173.86 0.00 140.49
2018-09-30 163.41 0.00 137.83
2018-06-30 148.53 0.00 120.15
2018-03-31 143.03 0.00 113.76
2017-12-31 138.20 0.00 119.01
2017-09-30 132.10 0.00 108.81
2017-06-30 125.93 0.00 103.79
2017-03-31 122.95 0.00 99.21
2016-12-31 117.27 0.00 95.76
2016-09-30 110.20 3.04 93.60
2016-06-30 105.14 5.29 93.93
2016-03-31 98.06 7.50 88.24
2015-12-31 95.30 9.70 91.12
2015-09-30 94.87 11.86 93.34
2015-06-30 95.06 20.93 104.14
2015-03-31 -3.91 22.34 4.24
2014-12-31 -3.15 19.35 2.30
2014-09-30
2014-06-30 3.21 17.50 2.12
2014-03-31 5.01 17.50 3.11
2013-12-31 7.85 17.50 6.73
2012-12-31 -9.04 10.50 1.73
  • Glaukos's level of debt (6.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (350.6% vs 6.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Glaukos has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Glaukos has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -49% per year.
X
Financial health checks
We assess Glaukos's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Glaukos has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6GJ Dividends

 What is Glaukos's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Glaukos dividends. Estimated to be 0% next year.
If you bought €2,000 of Glaukos shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Glaukos's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Glaukos's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6GJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6GJ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Glaukos has not reported any payouts.
  • Unable to verify if Glaukos's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Glaukos's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Glaukos has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Glaukos's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Glaukos's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Glaukos afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Glaukos has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6GJ Management

 What is the CEO of Glaukos's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Burns
COMPENSATION $5,198,717
AGE 57
TENURE AS CEO 17.2 years
CEO Bio

Mr. Thomas William Burns has been the Chief Executive Officer and President at Glaukos Corporation since march 2002. He is Director of Avedro, Inc. since July 18, 2018. Prior to Glaukos, Mr. Burns led Eyetech (Acquired by OSI Pharmaceuticals Inc.) as President and Chief Operating Officer. Mr. Burns was a co-founder of Chiron Vision and as Senior Vice President and General Manager, helped build that business from a start-up to a successful $310 million acquisition by Bausch & Lomb in 1998. He has had the privilege of leading world-class teams to create new commercial global markets by introducing entirely new market-classes in ophthalmology: the first foldable intraocular lenses, the first LASIK keratome, the first intraocular ophthalmic drug delivery implants (Vitrasert ), the first preservative-free artificial tears (Celluvisc and Refresh ), the first, foundational, customized LASIK technologies and the first MIGS (micro-invasive glaucoma surgery) implants to treat open-angle glaucoma. As a leading serial entrepreneur, Mr. Burns has raised a quarter billion dollars to date in private placements to build successful businesses. Mr. Burns has provided the leadership for Glaukos since its founding in 2001. He is a leader in the ophthalmic industry having built substantial value, delivered rapid growth and created entirely new commercial product classes and global markets in senior leadership roles at three major, successful start-up companies. He serves as a Director of Glaukos Corporation. He served as a Director of Eyetech. Mr. Burns received his bachelor s degree in history from Yale University.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Glaukos management team in years:

2.3
Average Tenure
57
Average Age
  • The tenure for the Glaukos management team is about average.
Management Team

Thomas Burns

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
57
TENURE
17.2 yrs

Joe Gilliam

TITLE
CFO & Senior VP of Corporate Development
COMPENSATION
$2M
AGE
42
TENURE
2 yrs

Chris Calcaterra

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
58
TENURE
2.3 yrs

Mory Gharib

TITLE
Co-Founder

Chris Lewis

TITLE
Director of Investor Relations

Robert Davis

TITLE
Senior VP
AGE
52
TENURE
3.9 yrs

Michele Allegretto

TITLE
Senior Vice President of Human Resources
TENURE
4 yrs

David Haffner

TITLE
Senior Vice President of New Technologies
TENURE
2.3 yrs

L. Katz

TITLE
Chief Medical Officer
TENURE
2.3 yrs

Jane Rady

TITLE
Senior Vice President of Corporate Strategy & Business Development
AGE
70
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Glaukos board of directors in years:

4.8
Average Tenure
58
Average Age
  • The tenure for the Glaukos board of directors is about average.
Board of Directors

Bill Link

TITLE
Chairman
COMPENSATION
$265K
AGE
72
TENURE
17.9 yrs

Thomas Burns

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
57
TENURE
17.2 yrs

Mark Foley

TITLE
Director
COMPENSATION
$235K
AGE
53
TENURE
4.8 yrs

Marc Stapley

TITLE
Director
COMPENSATION
$244K
AGE
48
TENURE
4.8 yrs

Gil Kliman

TITLE
Director
COMPENSATION
$225K
AGE
59
TENURE
12.3 yrs

Ike Ahmed

TITLE
Member of Scientific Advisory Board

Richard Lindstrom

TITLE
Member of Scientific Advisory Board
AGE
70

Thomas Samuelson

TITLE
Member of Scientific Advisory Board

David Hoffmeister

TITLE
Director
COMPENSATION
$232K
AGE
63
TENURE
4.8 yrs

Aimee Weisner

TITLE
Director
COMPENSATION
$225K
AGE
49
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Nov 18 Sell William Link Individual 13. Nov 18 15. Nov 18 -41,500 €51.43 €-2,113,557
31. Aug 18 Sell InterWest Partners LLC Company 29. Aug 18 29. Aug 18 -500,000 €51.62 €-25,810,526
31. Aug 18 Sell InterWest Partners LLC Company 30. Aug 18 30. Aug 18 -2,760 €53.57 €-147,848
X
Management checks
We assess Glaukos's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Glaukos has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6GJ News

Simply Wall St News

6GJ Company Info

Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company’s product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

Details
Name: Glaukos Corporation
6GJ
Exchange: DB
Founded: 1998
$2,173,199,007
36,402,966
Website: http://www.glaukos.com
Address: Glaukos Corporation
229 Avenida Fabricante,
San Clemente,
California, 92672,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE GKOS Common Stock New York Stock Exchange US USD 25. Jun 2015
DB 6GJ Common Stock Deutsche Boerse AG DE EUR 25. Jun 2015
Number of employees
Current staff
Staff numbers
437
Glaukos employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/21 22:28
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2019/05/21
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.